Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Nitric-oxide synthase, brain | Starlite/ChEMBL | References |
Bos taurus | Nitric-oxide synthase, endothelial | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Mus musculus | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0118 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0118 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0118 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0118 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0118 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0118 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0118 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0118 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.006 | 0.0151 | 0.0151 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0105 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0059 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0118 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0073 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0118 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0073 | 0.2407 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0118 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0118 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0105 | 0.7743 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0118 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0059 | 0 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0118 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0118 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0118 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0118 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 0.138 uM | Binding affinity to recombinant human neuronal NOS overexpressed in Escherichia coli assessed as production of nitric oxide from L-arginine measured for 5 mins by oxyhemoglobin NO capture assay | ChEMBL. | 25489882 |
Ki (binding) | = 0.183 uM | Binding affinity to recombinant rat neuronal NOS overexpressed in Escherichia coli assessed as production of nitric oxide from L-arginine measured for 5 mins by oxyhemoglobin NO capture assay | ChEMBL. | 25489882 |
Ki (binding) | = 3.4 uM | Binding affinity to recombinant mouse macrophage inducible NOS overexpressed in Escherichia coli assessed as production of nitric oxide from L-arginine measured for 5 mins by oxyhemoglobin NO capture assay | ChEMBL. | 25489882 |
Ki (binding) | = 10.5 uM | Binding affinity to recombinant bovine endothelial NOS overexpressed in Escherichia coli assessed as production of nitric oxide from L-arginine measured for 5 mins by oxyhemoglobin NO capture assay | ChEMBL. | 25489882 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.